Medizinische Universität Graz - Research portal
Selected Publication:
Kasper, S; Quiner, S; Barnas, C; Fabisch, H; Haushofer, M; Sackel, C; Konig, P; Lingg, A; Platz, T; Rittmannsberger, H; Stuppack, C; Willeit, M; Zapotoczky, HG.
Zotepine in the treatment of acute hospitalised schizophrenic episodes
PSYCHOPHARMAKOTHERAPIE. 1999; 6(3): 96-99.
Web of Science
- Co-authors Med Uni Graz
- Fabisch Johann
- Altmetrics:
- Abstract:
- The atypical antipsychotic zotepine was studied in a drug surveillance study in 108 schizophrenic patients within a multi-centre trial in 12 hospitals in Austria. Within the dosage (range 50-450 mg, mean at the end of the study, 207 +/- 125 mg/day) there was a significant reduction of positive as well as negative symptoms. There was no increase of extra-pyramidal side effects during the study and a significant decrease of akathisia scores. Altogether the medication was well tolerated and safe during the 42 days observation period Given the fact that zotepin affects both positive and negative symptoms and is not accompanied by EPS side effects the classification as an atypical antipsychotic seems to be justified.
- Find related publications in this database (Keywords)
- schizophrenia
- antipsychotics
- atypical antipsychotics
- zotepine
- drug surveillance study